SLNO Soleno Therapeutics Inc

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences:

Event: Guggenheim Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 10:00 AM ET

Event: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 4:45 PM ET

Event: Jefferies London Healthcare ConferenceDate: Wednesday, November 20, 2024Time: 8:00 AM GT

A live audio webcast and replay of the Guggenheim and Jefferies events will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company recently submitted an NDA to the FDA, supported by its Phase 3 development program, for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS). For more information, please visit www.soleno.life.

Corporate Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578